Clinical trial · Observational
Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT06400550CI-TRIAL-00113217recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this study is to observe metabolic features associated with human melanoma tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Melanoma (Skin) | Melanoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- 13C-glucose infusion
- description
- Tumor samples of patients who receive the optional 13C-glucose infusion will be studied using flux analysis and metabolomic profiling.
- label
- No 13C-glucose infusion
- description
- Tumor samples of patients who do not receive the optional 13C-glucose infusion will be studied using metabolomic profiling alone.
Primary outcomes (1)
- measure
- Glucose Utilisation in the TCA cycle
- timeFrame
- 5 years
- description
- In patients receiving a \[U-13C\]Glucose infusion, assess glucose utilization in the TCA cycle by melanoma tumors (defined as fractional enrichment of 13C-label in TCA metabolites)
Secondary outcomes (3)
- measure
- Relapse free survival
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with known or probable malignant melanoma lesions requiring surgical biopsy or excision. * Subjects of all races and ethnic origins over age 18. Exclusion Criteria: * Not a surgical candidate * Poorly controlled diabetes
References
Publications (0)
Data not yet available
No reference posted for this study.